Lipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.com

Analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 12.8 %

Lipocine stock opened at $6.51 on Thursday. Lipocine has a 12 month low of $2.31 and a 12 month high of $6.70. The company’s fifty day simple moving average is $4.30 and its 200-day simple moving average is $3.37. The stock has a market cap of $34.63 million, a P/E ratio of -2.13 and a beta of 1.05.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.11. The business had revenue of $0.22 million for the quarter. On average, equities research analysts expect that Lipocine will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lipocine

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in Lipocine in the 1st quarter worth $54,000. Renaissance Technologies LLC lifted its position in shares of Lipocine by 474.5% during the 2nd quarter. Renaissance Technologies LLC now owns 81,006 shares of the specialty pharmaceutical company’s stock worth $65,000 after purchasing an additional 66,906 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Lipocine by 524.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 74,428 shares during the period. Millennium Management LLC acquired a new stake in Lipocine in the 2nd quarter valued at approximately $160,000. Finally, State Street Corp increased its position in Lipocine by 7.5% in the 1st quarter. State Street Corp now owns 327,405 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 22,788 shares during the period. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.